Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumiracoxib Extension Study in Knee Osteoarthritis
NCT00475800Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2004
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of lumiracoxib in osteoarthritis (OA), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability at 39 weeks. Started Jan 2004; status: completed.
02
Drugs
lumiracoxib
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00475800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00475800.